Since M2 macrophages contribute to maintenance of the tumor immunosuppressive microenvironment that promotes drug resistance and immune escape through activation of the MERTK signaling pathway, targeting MERTK has become a potential therapeutic strategy for fighting NSCLC. Here, MERTK is linked to neoplasm.